Molecular Formula	C21H27N5O4S
Molecular Weight	445.5
Structure
State	solid
Clearance	The mean total body clearance of glipizide was approximately 3 L/hr following administration of single intravenous doses in patients with type 2 diabetes mellitus.[label]
Volume of distribution	The mean volume of distribution was approximately 10 L following administration of single intravenous doses in patients with type 2 diabetes mellitus.[label] In mice and rat studies, the presence of the drug and its metabolites was none to minimal in the fetus of pregnant female animals.[L6745] Other sulfonylurea drugs were shown to cross the placenta and enter breast milk [T28] thus the potential risk of glipizide in fetus or infants cannot be excluded.
Route of elimination	Glipizide is mainly eliminated by hepatic biotransformation, where less than 10% of the initial dose of the drug can be detected in the urine and feces as unchanged glipizide. About 80% of the metabolites of glipizide is excreted in the urine while 10% is excreted in the feces.[label]
Protein binding	Glipizide is about 98-99% bound to serum proteins, with albumin being the main plasma protein.[label]
Half life	The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.[label]
Absorption	Gastrointestinal absorption of glipizide is uniform, rapid, and essentially complete.[A179485] The absolute bioavailability of glipizide in patients with type 2 diabetes receiving a single oral dose was 100%. The maximum plasma concentrations are expected to be reached within 6 to 12 hours following initial dosing. The steady-state plasma concentrations of glipizide from extended-release oral formulations are maintained over the 24-hour dosing interval.[label] In healthy volunteers, the absorption of glipizide was delayed by the presence of food but the total absorption was unaffected.[L6745]

Organism	Test type	Route	Dose (normalized dose)	Effect	Source
rat	LDLo	oral	> 4gm/kg (4000mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 208, 1971.
child	TDLo	oral	379ug/kg (0.379mg/kg)	endocrine: hypoglycemia	Annals of Emergency Medicine. Vol. 31, Pg. 773, 1998.
rat	LD50	intraperitoneal	1200mg/kg (1200mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 208, 1971.
mouse	LD50	intraperitoneal	> 3gm/kg (3000mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 208, 1971.
guinea pig	LDLo	oral	> 4gm/kg (4000mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 208, 1971.
guinea pig	LD50	intraperitoneal	2400mg/kg (2400mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 208, 1971.
mouse	LDLo	oral	> 4gm/kg (4000mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 208, 1971.

Blood glucose decreased

Diabetic retinopathy

Glucose-6-phosphate dehydrogenase deficiency

Hyperglycaemia

Ketosis

Nephropathy

Neuropathy peripheral

Obesity

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Weight decreased

Asthenia

Diarrhoea

Dizziness

Flatulence

Headache

Nervousness

Tension

Tremor

094G619	1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea	1-Cyclohexyl-3-{{p=[2-[5-methylpyrazine-carboxamido)-ethyl]phenyl}sulphonyl}urea
1-cyclohexyl-3-(4-(2-(2-methylpyrazine-5-carboxamido)ethyl)phenylsulfonyl)urea	1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea	1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea
29094-61-9	29094-66-4	AB0012143
AC-15789	AKOS005564405	ANW-41980
API0002842	Aldiab	BBL028143
BCP09195	BDBM50012956	BG0209
BIDD:GT0476	BPBio1_000224	BRD-K12219985-001-04-8
BRD-K12219985-001-15-4	BRN 0903495	BSPBio_000202
BSPBio_001349	Bio1_000074	Bio1_000563
Bio1_001052	Bio2_000069	Bio2_000549
C-22417	C21H27N5O4S	CAS-29094-61-9
CBiol_001788	CC-28982	CCG-204710
CHEBI:5384	CHEMBL1073	CP 28,720
CP 28720	CP 28720;K 4024	CP-28,720
CP-28720	CPD000058455	CS-2239
CTK8B3212	Certified Reference Material	D00335
DB01067	DSSTox_CID_20676	DSSTox_GSID_40676
DSSTox_RID_79535	DTXSID0040676	Digrin
Dipazide	EINECS 249-427-6	EU-0100621
FT-0626714	FT-0659737	G-117
G0369	GTPL6821	Glibenese
Glibetin	Glican	Glide
Glidiab	Glidiazinamide	Glipid
Glipizibe	Glipizida	Glipizida [INN-Spanish]
Glipizide (Glucotrol)	Glipizide (USP/INN)	Glipizide [USAN:BAN:INN]
Glipizide [USAN:USP:INN:BAN]	Glipizide(Glucotrol)	Glipizide, 98+%
Glipizide, European Pharmacopoeia (EP) Reference Standard	Glipizide, Pharmaceutical Secondary Standard	Glipizide, United States Pharmacopeia (USP) Reference Standard
Glipizide, solid	Glipizide,(S)	Glipizidum
Glipizidum [INN-Latin]	Gluco-Rite	Glucolip
Glucotrol	Glucotrol (TN)	Glucotrol XL
Glucozide	Glupitel	Glupizide
Glyde	Glydiazinamide	Glypidizine
HMS1361D11	HMS1568K04	HMS1791D11
HMS1989D11	HMS2089C21	HMS2093J09
HMS2095K04	HMS2233N11	HMS3259K12
HMS3261N04	HMS3369L12	HMS3402D11
HMS3655G04	HMS3712K04	HY-B0254
IDI1_033819	K 4024	K-4024
KBio2_000069	KBio2_002637	KBio2_005205
KBio3_000137	KBio3_000138	KBioGR_000069
KBioSS_000069	KS-1068	LP00621
LS-159679	Lopac-G-117	Lopac0_000621
MCULE-5142805548	MFCD00072159	MLS000069386
MLS001148176	Melizide	Metaglip
Metaglip (Salt/Mix)	Mindiab	Minidab
Minidiab	Minodiab	N-(2-[4-(([(Cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-5-methyl-2-pyrazinecarboxamide
N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide	N-(4-(.beta.-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea	N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-methylpyrazine-2-carboxamide
N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea	N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-5-methylpyrazine-2-carboxamide	N-[2-(4-{[(cyclohexylamino)carbonylamino]sulfonyl}phenyl)ethyl](5-methylpyrazi n-2-yl)carboxamide
N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide	N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyrazine-2-carboxamide	N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide
N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea	NC00564	NCGC00015462-01
NCGC00015462-02	NCGC00015462-03	NCGC00015462-04
NCGC00015462-05	NCGC00015462-06	NCGC00015462-07
NCGC00015462-08	NCGC00015462-09	NCGC00015462-10
NCGC00015462-11	NCGC00015462-12	NCGC00015462-14
NCGC00016802-01	NCGC00023748-03	NCGC00023748-04
NCGC00023748-05	NCGC00023748-06	NCGC00023748-07
NCGC00255522-01	NCGC00261306-01	NSC-759120
NSC759120	Napizide	Opera_ID_1908
Ozidia	Pharmakon1600-01505433	Prestwick0_000131
Prestwick1_000131	Prestwick2_000131	Prestwick3_000131
Prestwick_242	Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-	Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-
Q3108899	SAM002564210	SBI-0050603.P002
SC-13933	SCHEMBL17094	SMR000058455
SPBio_002141	SR-01000000010	SR-01000000010-2
SR-01000000010-5	ST50826363	STK631952
SW196549-3	Sucrazide	TC-063559
TK 1320	Tox21_110156	Tox21_110156_1
Tox21_301834	Tox21_500621	UNII-X7WDT95N5C
Urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)-	W-107005	X7WDT95N5C
Z1880962274	ZINC537795	ZJJXGWJIGJFDTL-UHFFFAOYSA-N
glipizide	glipizide/glucotrol	s1715

DrugBank Name	Glipizide
DrugBank	DB01067
CAS Number	172964-66-8, 29094-61-9, 29094-66-4
PubChem Compound	3478
KEGG Drug	D00335
PubChem.Substance	46505865
ChEBI	5384
PharmGKB	PA449762
ChemSpider	3359
BindingDB	50012956.0
TTD	DAP000920
Wikipedia	Glipizide